Key Points
Analysts expect $0.27 EPS and $3.84B revenue on May 7, 2026.
KVUE has beaten EPS estimates in recent quarters but consistently missed revenue expectations.
Meyka AI rates KVUE B+, reflecting solid profitability but limited growth prospects.
Investors should focus on margin trends and segment performance rather than headline revenue growth.
Kenvue Inc. (KVUE) reports earnings on May 7, 2026, with Wall Street expecting $0.27 EPS and $3.84 billion in revenue. The consumer health company faces a critical test after mixed recent results. Last quarter, KVUE beat EPS estimates but revenue came in slightly below expectations. Investors will scrutinize whether the company can sustain momentum across its three key segments: Self Care, Skin Health and Beauty, and Essential Health. With the stock trading at $17.37 and a B+ grade from Meyka AI, this earnings report could significantly impact shareholder sentiment heading into the second half of 2026.
What Analysts Expect from KVUE Earnings
Wall Street has set modest expectations for Kenvue’s upcoming earnings report. Analysts project $0.27 earnings per share and $3.84 billion in quarterly revenue. These estimates represent a slight increase from the previous quarter’s $0.2227 EPS estimate, though revenue expectations remain relatively flat compared to recent quarters.
EPS Estimate Analysis
The $0.27 EPS estimate marks a meaningful recovery from earlier guidance. Last quarter, KVUE delivered $0.27 actual EPS, beating the $0.2227 estimate by roughly 21%. This strong beat suggests improving operational efficiency and cost management. If the company repeats this performance, it could signal sustained profitability gains across its consumer health portfolio.
Revenue Estimate Breakdown
The $3.84 billion revenue estimate sits between recent quarterly results. Q1 2026 delivered $3.78 billion, while Q4 2025 generated $3.74 billion. This modest growth trajectory reflects the mature nature of Kenvue’s markets. Investors should watch whether the company can drive volume growth or pricing power across its iconic brands like Tylenol, Neutrogena, and Listerine.
Historical Earnings Trend
Kenvue shows an improving earnings trend despite flat revenue. EPS estimates have climbed from $0.2275 in Q2 2025 to $0.27 today. This 19% improvement in earnings estimates reflects better margin management and operational leverage. The company appears to be squeezing more profit from each dollar of sales, a positive sign for long-term shareholder value.
Beat or Miss: What History Tells Us
Kenvue’s recent earnings track record suggests a company that consistently beats EPS expectations but struggles with revenue guidance. This pattern matters significantly for stock movement after the May 7 report.
Recent Beat/Miss Pattern
Last quarter, KVUE delivered a 21% EPS beat against estimates, posting $0.27 actual versus $0.2227 expected. However, revenue came in slightly below at $3.78 billion versus $3.69 billion estimated. Two quarters prior, the company beat EPS ($0.24 actual versus $0.2275 estimated) but again missed revenue ($3.74 billion versus $3.68 billion estimated). This pattern suggests management is conservative with EPS guidance but optimistic on revenue.
Probability of Beat
Based on historical performance, KVUE has a strong likelihood of beating the $0.27 EPS estimate. The company has beaten EPS in two consecutive quarters. However, revenue could be the wildcard. If KVUE follows its pattern, expect revenue near or slightly below the $3.84 billion estimate. Investors should focus on margin expansion rather than top-line growth.
What Could Trigger a Miss
A revenue miss would likely stem from weakness in the Self Care segment, which includes pain relief and cold remedies. Seasonal demand fluctuations and competitive pricing pressure from generic alternatives could pressure results. Additionally, any supply chain disruptions or inventory corrections at retail partners would hurt revenue.
Key Metrics and What to Watch
Beyond headline numbers, several metrics will determine whether KVUE’s earnings meet investor expectations and support the stock’s valuation.
Segment Performance
The Self Care segment, featuring Tylenol and Nicorette, generates roughly 40% of revenue. Watch for pricing power in this mature category. The Skin Health and Beauty segment, anchored by Neutrogena and Aveeno, should show steady growth from premiumization trends. Essential Health, including Listerine and Johnson’s baby products, typically delivers stable margins. Management commentary on each segment’s growth trajectory will matter more than absolute numbers.
Margin Trends
Kenvue’s gross margin sits at 58.1%, while operating margin stands at 17.9%. Investors should monitor whether these margins expand or contract. Rising input costs or promotional activity could pressure margins. Conversely, operational efficiency gains could drive margin expansion. The company’s ability to maintain pricing while managing costs will determine profitability sustainability.
Cash Flow Generation
Operating cash flow per share reached $1.15, while free cash flow per share hit $0.90. The company’s dividend yield of 4.75% depends on sustained cash generation. Watch for any changes in capital allocation priorities or dividend guidance. Strong free cash flow supports the dividend and signals financial health.
Debt and Leverage
Kenvue carries a debt-to-equity ratio of 0.79, which is moderate for a consumer staples company. The company’s interest coverage ratio of 6.68 indicates comfortable debt servicing. Any commentary on refinancing plans or debt reduction would be noteworthy for credit-sensitive investors.
Meyka AI Grade and Investment Outlook
Meyka AI rates KVUE with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
What the B+ Grade Means
The B+ rating suggests KVUE is a solid performer relative to peers but not exceptional. The company scores well on profitability metrics like ROE (13.9%) and ROA (5.4%), indicating efficient asset utilization. However, the stock’s PE ratio of 22.7 sits above historical averages, suggesting current valuations price in future growth. The grade reflects a balanced risk-reward profile suitable for income-focused investors.
Analyst Consensus
Wall Street consensus leans toward Hold, with 1 Buy, 7 Holds, and 0 Sells among tracked analysts. This neutral stance reflects uncertainty about growth prospects. The consumer health sector faces structural headwinds from e-commerce competition and private label alternatives. However, Kenvue’s brand strength and market position provide downside protection.
Stock Valuation Context
At $17.37, KVUE trades near its 50-day average of $17.70 but well below its 52-week high of $25.17. The stock has declined 26.4% over the past year, creating potential value for contrarian investors. The 4.75% dividend yield provides income support, making KVUE attractive for yield-seeking portfolios despite growth concerns.
Final Thoughts
Kenvue’s May 7 earnings will reveal if the company can maintain EPS growth while addressing revenue stagnation. Analysts expect $0.27 EPS and $3.84 billion revenue, with likely EPS beats but potential revenue misses. Better operational execution has improved earnings, yet flat revenue growth reflects mature market challenges. With a B+ grade and 4.75% dividend yield, KVUE attracts income investors but concerns growth-focused traders. Focus on margin expansion and segment guidance rather than headline revenue. Strong cash flow and moderate leverage provide stability, though the 26% annual decline signals investor skepticism about long-term growth in consumer health.
FAQs
What EPS and revenue are analysts expecting from KVUE earnings?
Wall Street expects Kenvue to report $0.27 earnings per share and $3.84 billion in revenue for the upcoming quarter. These estimates represent modest growth compared to recent quarters and reflect expectations for steady operational performance.
Has KVUE beaten or missed earnings estimates recently?
Kenvue has beaten EPS estimates in the last two quarters, posting $0.27 versus $0.2227 expected and $0.24 versus $0.2275 expected. However, revenue has consistently missed or come in slightly below estimates, suggesting conservative EPS guidance but optimistic revenue forecasts.
What is Meyka AI’s grade for KVUE and what does it mean?
Meyka AI rates KVUE with a B+ grade, reflecting solid performance relative to peers. The grade factors in profitability metrics, sector comparison, and analyst consensus. It suggests balanced risk-reward suitable for income investors but limited growth prospects.
What should investors watch for in KVUE’s earnings report?
Focus on segment performance, particularly Self Care and Skin Health margins. Monitor cash flow generation supporting the 4.75% dividend, debt management, and management guidance on pricing power. Margin trends matter more than absolute revenue growth.
Why has KVUE stock declined 26% over the past year?
The decline reflects investor concerns about mature market growth, e-commerce competition, and private label pressure. While the company generates strong cash flow and maintains a healthy dividend, growth prospects remain limited, causing valuation compression.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)